LH launches the first FDA-cleared blood test for Alzheimer's, boosting access to early diagnosis and nudging its stock higher.

Labcorp Holdings (LH) experienced a 10% price increase in the past month, which aligns with its recent strategic advancements including the launch of Lumipulse® pTau-217/Beta Amyloid 42 Ratio, marking ...

Labcorp introduces US FDA approved blood test, Lumipulse pTau-217/Beta Amyloid 42 Ratio for Alzheimer's disease: Burlington, North Carolina Tuesday, August 19, 2025, 14:00 Hrs [IS ...

Labcorp has launched the first blood-based in-vitro diagnostic test cleared by the Food and Drug Administration to aid in the diagnosis of Alzheimer's disease.

Seniors experiencing memory problems and cognitive decline now have access to a new diagnostic blood test to detect Alzheimer’s disease. Labcorp this week unveiled the first Food and Drug ...

Prenatal exposure to chlorpyrifos -- mostly attributable to indoor residential spraying for pests, prevalent in inner-city ...

FutureWise Research today announces the upcoming release of its comprehensive report, Alzheimer’s Disease Diagnostic Market – ...

Labcorp raised its annual profit forecast on Thursday after beating Wall Street estimates for second-quarter profit and revenue on robust demand for its diagnostic tests, sending its shares up ...

A new campaign invites people to chew over the idea of becoming stem cell donors—literally. | A new campaign invites people to chew over the idea of becoming stem cell donors—literally.

Labcorp cut a ribbon on its 18th patient service center in West Virginia Thursday. They also held an open house of the new facility.

Labcorp Holdings Inc. (NYSE:LH) Q2 2025 Earnings Conference Call July 24, 2025 9:00 AM ETCompany ParticipantsAdam H.

Alzheimer’s disease is a devastating condition that affects more than 7 million Americans, according to the Alzheimer’s Association. As the Baby Boomer generation ages, this number is estimated to ...